PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16505027-1	2006	PURPOSE: This study analyzes additional mechanisms behind the ocular hypotensive effect of prostaglandin F (PGF) receptor (FP receptor) agonists PGF2alpha and fluprostenol (fluprostenol-isopropyl ester [travoprost]), which reduce intraocular pressure (IOP) in patients with glaucoma probably by enhancing uveoscleral flow.	Travoprost	203-213	prostaglandin F receptor	Homo sapiens	91-121	
21060666-5	2010	In addition, the long duration of action of travoprost can also provide better control of IOP fluctuation, probably due to its stronger prostaglandin F receptor mechanism.	Travoprost	44-54	prostaglandin F receptor	Homo sapiens	136-160	
12204714-4	2002	As latanoprost and travoprost are selective agonists for the prostaglandin F(2alpha) receptor, it is likely that the phenomenon is mediated by this receptor.	Travoprost	19-29	prostaglandin F receptor	Homo sapiens	61-93	
31462124-4	2019	Latanoprost, Bimatoprost, Travoprost, and Tafluprost are clinically used as antiglaucoma drugs and act as agonists of the PGF2alpha receptor.	Travoprost	26-36	prostaglandin F receptor	Homo sapiens	122-140